About Our Client:
Our client, US-based biotech company involved in the discovery and development of small molecule therapeutics for the treatment of cardiovascular disease.
- The molecule has good solid-state properties but low solubility
- The molecule is neutral in nature and does not have any detectable solubility across the pH range expected in the GIT
- The molecule has less than 10% bioavailability (BA) in preclinical species
To enable toxicity studies, the molecule required formulation development that could support a high dose delivery while providing a linear dose exposure in preclinical studies
Download this case study to learn how Aragen integrated pharmaceutics plus pharmacokinetics approach avoids potential delays and helps achieve substantial savings in time and development costs.